文献速递糖尿病

芬兰DIPP研究中胰岛自身免疫与1型糖尿病进展:遗传易感儿童有无一级亲属患病的比较

Islet autoimmunity and progression to type 1 diabetes in the Finnish DIPP study: comparison between genetically susceptible children with and without an affected first-degree relative.
PubMed 文献 · Diabetologia · 2025-11-08

该前瞻性出生队列纳入1334名至少一种胰岛自身抗体阳性的HLA易感儿童,比较有无一级亲属患1型糖尿病者的自身免疫启动与进展。有患病一级亲属者GADA及多抗体阳性更常见,进展至临床糖尿病比例更高(55.9% vs 38.9%),且从血清转换到临床糖尿病时间更短(2.7 vs 3.6年)。

要点

  • 有患病一级亲属的遗传易感儿童在血清转换时更常GADA及多抗体阳性。
  • 有患病一级亲属者随访中IAA、GADA、IA-2A及多抗体阳性更常见,进展至糖尿病更快。
  • 父亲患1型糖尿病者血清转换时多抗体阳性率高于母亲患病者(39.4% vs 20.0%)。

核心结论

  • 有患病一级亲属的遗传易感儿童在血清转换时更常GADA及多抗体阳性,尤其父亲患病者。
  • 有患病一级亲属者随访中IAA、GADA、IA-2A阳性更常见,进展至临床1型糖尿病更多且更快。

研究设计与样本

  • 芬兰DIPP前瞻性出生队列,随访HLA易感儿童从出生起检测胰岛自身抗体(IAA、GADA、IA-2A、ZnT8A)。
  • 共1334名确认至少一种胰岛自身抗体阳性的儿童,其中145名(10.9%)出生时有一级亲属患1型糖尿病。

主要发现

  • 中位随访8.6年,另87名儿童的父母后续患1型糖尿病。
  • 血清转换时FDR+和FDR-后FDR+儿童GADA及多抗体阳性显著多于FDR-儿童。
  • 三组血清转换年龄相似(中位2.7 vs 2.1 vs 3.0年)。
  • 随访期间FDR+和FDR-后FDR+儿童IAA、GADA、IA-2A及多抗体阳性更常见,进展至糖尿病比例分别为55.9% vs 57.5% vs 38.9%。
  • FDR+儿童从血清转换到临床糖尿病时间显著短于FDR-儿童(2.7 vs 3.6年)。

关键数值与推荐

  • 血清转换时FDR+和FDR-后FDR+儿童GADA及多抗体阳性显著多于FDR-儿童。
  • 随访期间FDR+和FDR-后FDR+儿童IAA、GADA、IA-2A及多抗体阳性更常见,进展至糖尿病比例分别为55.9% vs 57.5% vs 38.9%。
  • FDR+儿童从血清转换到临床糖尿病时间显著短于FDR-儿童(2.7 vs 3.6年)。
  • 父亲患1型糖尿病者血清转换时多抗体阳性率39.4%,母亲患病者为20.0%。

临床怎么用

  • 对有1型糖尿病一级亲属的遗传易感儿童应加强胰岛自身抗体监测。
  • 父亲患1型糖尿病者多抗体阳性风险更高,可考虑更密切随访。
  • 干预与筛查研究设计时应考虑家族史对自身免疫进展的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

AIMS/HYPOTHESIS: Islet autoimmunity during presymptomatic type 1 diabetes is heterogeneous. We hypothesised that a positive family history of type 1 diabetes is associated with specific characteristics of the autoimmune process resulting in clinical diabetes. In a prospective birth cohort study, we compared the initiation and evolution of islet autoimmunity and the rate of progression from islet autoimmunity to diabetes between children with and without a first-degree relative (FDR) with type 1 diabetes. METHODS: In the Finnish Type 1 Diabetes Prediction and Prevention (DIPP) study, we prospectively followed children with HLA-conferred susceptibility from birth for the appearance of islet autoantibodies (IAA, GADA, IA-2A, ZnT8A), further development of islet autoimmunity, and progression to clinical diabetes. The presence of type 1 diabetes among their FDRs was recorded at the time of birth, and the family history data was updated during the follow-up period. RESULTS: Among a total of 1334 children with confirmed positivity for at least one islet autoantibody, 145 (10.9%) had one or more FDRs with type 1 diabetes at the time of birth (FDR+). During a median follow-up period of 8.6 years, FDRs of an additional 87 children developed type 1 diabetes (FDR- FDR+). At seroconversion, both FDR+ and FDR- FDR+ children were significantly more often positive for GADA and multiple autoantibodies than children without affected FDRs (FDR-). The seroconversion age was similar between the three groups (median 2.7 vs 2.1 vs 3.0 years in FDR+, FDR- FDR+ and FDR- children, respectively). During the follow-up period, FDR+ and FDR- FDR+ children more often had IAA, GADA, IA-2A and multiple autoantibodies than FDR- children, and progressed more frequently to diabetes (55.9 vs 57.5 vs 38.9%, respectively). Time from seroconversion to clinical diabetes was significantly shorter in FDR+ children compared with FDR- children (2.7 vs 3.6 years). Children with paternal type 1 diabetes at birth (n=71; i.e., the father had type 1 diabetes) were twice as often positive for multiple autoantibodies at seroconversion as those with maternal type 1 diabetes (n=50; i.e. the mother had type 1 diabetes) (39.4% vs 20.0%). CONCLUSIONS/INTERPRETATION: At seroconversion, genetically susceptible children who had one or more FDRs with type 1 diabetes, especially an affected father, were more often positive for GADA and multiple islet autoantibodies. During the follow-up period, children with an affected FDR were more often positive for IAA, GADA and IA-2A, and progressed to clinical type 1 diabetes more often and faster than children without an affected FDR. These data should be considered when designing intervention and screening studies.

来源:Diabetologia,查看原文。版权归原作者所有。

引用

  1. Kuusela S, Koskenniemi JJ, Valtanen T, et al. Islet autoimmunity and progression to type 1 diabetes in the Finnish DIPP study: comparison between genetically susceptible children with and without an affected first-degree relative. Diabetologia. 2025. PMID: 41204978. doi:10.1007/s00125-025-06573-6

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。